Taking Unparalleled Results to Treat the Next Epidemic
Since donning its new corporate identity earlier this year, Algernon Pharmaceuticals Inc. (CSE: AGN, OTCQB: BTHCF, Forum) has been busy advancing its research and its business. Much like the classic novel the clinical stage Company derived its name from, which built its theme around change, Algernon is shifting to become a phase II clinical trial Company. Having changed its name to Algernon in February 2019, the corporate shift was intended to align its operation with its main strategy to be a global leader in the treatment of liver disease, non-alcoholic steatohepatitis (NASH), chronic kidney disease (CKD) and inflammatory bowel disease (IBD). NASH is a common liver …
Novartis buys NASH biotech IFM Tre in potential $1.575 billion deal
Novartis is to buy US biotech IFM Tre, adding a potential drug for the fatty liver disease known as NASH to its pipeline. This news commentary discusses the Novartis acquisition of one clinical and two preclinical drugs targeting the NLRP3 inflammasome, which could provide therapies for several metabolic, fibrotic, autoimmune, and neurologic diseases. NLRP3 drugs are of interest to pharma and biotech firms researching drugs for a range of diseases. These include non-alcoholic steatohepatitis (NASH), the fatty liver disease for which there is no approved treatment. Gary Glick, CEO, and co-founder of IFM Therapeutics said: “Based on substantial pre-clinical and translational …
Biotechnology Companies Ramp up Funding as Deadly Diseases Come Into the Spotlight
News commentary on marketwatch.com about Algernon Pharmaceuticals. The article addresses how biotechnology is rapidly and continually evolving each year with new innovative therapies and drugs, and how the market valued at USD 399.4 Billion in 2017 is projected to witness a robust CAGR of 9.9% from 2018 to 2024. This news commentary talks about Idiopathic Pulmonary Fibrosis (IPF) studies and how a successful IPF in vivo study for NP-251 would mean that Algernon could begin planning an additional phase II study for its fourth major global disease. A chest radiograph of a patient with IPF. Source: IPFeditor, on Wikipedia Read the full …
FDA Grants Breakthrough Status to Biopharma’s Lead Candidate for Liver Disease
Article from streetwisereports.com discussing how the advancements to Phase 2b are the most valuable asset to CymaBay and many Biotech companies. The research report also addresses how the analyst Yasmeen Rahimi reported that CymaBay Therapeutics had a strong Q1/19 with respect to continued execution of its clinical programs for its most advanced therapeutic, seladelpar, in nonalcoholic steatohepatitis (NASH) and primary biliary cholangitis (PBC). Periportal steatosis of the liver. Source: Nephron Read the full article on the StreetWise Reports website …
About Us
Latest News
